Smital Shah
CIK: 0001808821
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
LYEL
Lyell Immunopharma, Inc.
Officer
Discretionary Trading P&L
Holdings
About Shah Smital
Shah Smital (SEC CIK 0001808821) files insider reports with the SEC as Chief Fin. and Bus. Officer of Lyell Immunopharma, Inc. (LYEL).
Signal8 holds 2 ownership filings by Shah Smital (1 Form 3, 1 Form 4), filed on Mar 16, 2026. Those filings report 1 transaction, the latest on Mar 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Shah Smital's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Shah Smital
- Mar 9, 2026: Grant or award of LYEL derivative securities (Form 4, code A).
Other insiders filing for Lyell Immunopharma, Inc. (LYEL)
- Aguirre Jarrad Mattieu, Chief Medical Officer
- Shook David, Chief Medical Officer
- Seely Lynn, President and CEO
- Hill Stephen J., Chief Operating Officer
- Lee Gary K., Chief Scientific Officer
- Bulis Veronica Sanchez, VP, Corporate Controller